



B

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Herbert HERZOG

Art Unit: 1635

Application No.: 09/719,088 ✓

Examiner: Jon E. Angell

Filed: December 8, 2000

Attorney Dkt. No.: 12020-0003

For: NPY-Y7 RECEPTOR GENE

REQUEST FOR ACKNOWLEDGEMENT OF IDS


ATTN: BOX ISSUE FEE
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Applicant filed an Information Disclosure Statement, PTO-1449 and 2 references on December 8, 2000 with the filing of the application (copy enclosed) and we have yet to receive an acknowledgement from the Examiner that the cited references have been considered and made of record. As this application has been allowed, and the Issue Fee is due to be paid by April 15, 2004, Applicant respectfully requests acknowledgment of the filed Information Disclosure Statement as soon as possible.

Applicant submits that there is no fee required for this submission, however, please charge any fee deficiency or credit any overpayment to Deposit Account No. 50-1088.

Respectfully submitted,
CLARK & BRODY



Christopher W. Brody
Registration No. 33,613

Customer No. 22902
1750 K Street NW, Suite 600
Washington DC 20006
Telephone: 202-835-1111
Facsimile: 202-835-1755
Date: February 27, 2004

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

12020-0003

In Re Application Of: HERZOG

Serial No.

PCT/AU99/00523

Filing Date

Int'l: 29 June 1999

Examiner

Group Art Unit

Title: NPY-Y7 Receptor Gene

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
12020-0003

In Re Application Of: **HERZOG**

Serial No.
PCT/AU99/00523

Filing Date
Int'l: 29 June 1999

Examiner

Group Art Unit

Title: **NPY-Y7 Receptor Gene**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **50-1088** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

***This certificate may only be used if paying by deposit account.**

Christopher W. Brody
Signature

Christopher W. Brody, Reg. No. 33,613
Clark & Brody
1750 K Street, NW, Suite 600
Washington, DC 20006

Telephone: 202-835-1753
Facsimile: 202-835-1755

CC:

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

Dated: **December 8, 2000**

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY DOCKET NO.

12020-0003

SERIAL NO.

PCT/AU99/00523

HERZOG

FILING

Int'l: 29 June 1999

GROUP

FEB 27 2004

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0884387 A	12/16/98	Europe				
	WO 96/34877	11/7/96	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Biochem. Biophys. Res. Comm. 256, pages 352-6 (1999) "Sequence and tissue distribution of a novel G-protein-coupled receptor expressed prominently in human placenta." Cikos, W. et al.
		Trends in Neuroscience 20(7) pages 294-8 (1997) "Y-receptor subtypes-how many more?" Blomqvist, A.G. and Herzog, H.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.